ESMO Virtual Plenary: February 2023

Welcome and introduction, Scientific background and context
Florian Lordick, Leipzig University Medical Center, Leipzig, Germany

Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
Sun Young Rha, Yonsei University, Seoul, Republic of Korea

Critical analysis and perspectives (ESMO)
Elizabeth Smyth, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

AACR expert commentary
Brian S. Henick, Columbia University Irving Medical Center / Herbert Irving Comprehensive Cancer Center, New York, NY, USA

Discussion and Q&A (i)
Faculty and online audience

Virtual Plenary Expert Insights: Webcast of 16 February presentations, Discussion and Q&A (ii)
Faculty and online audience

Chair: Kei Muro, Aichi Cancer Center Hospital, Nagoya, Japan

Sun Young Rha, Yonsei University, Seoul, Republic of Korea

Elizabeth Smyth, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Matthew Chau Hsien Ng, National Cancer Centre Singapore, Singapore

Li-Tzong Chen, National Health Research Institutes, Tainan City, Taiwan